Liposome compositions for the delivery of macromolecules

• US 20050260260A1
• Filed: 05/19/2005
• Published: 11/24/2005
• Est. Priority Date: 05/19/2004
• Status: Abandoned Application

• Current Assignee: Bret Coldren, Edward Kisak
• Original Assignee: Bret Coldren, Edward Kisak
• Inventors: Coldren, Bret, Kisak, Edward
• Application Number:
  US11/132,368
• Publication Number:
  US 20050260260A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911

Abstract

This invention provides for a liposome composition which demonstrates greatly increased therapeutic efficacy when used to deliver encapsulated macromolecular drugs. The liposome composition excludes the use of sterols, sterol derivatives, and cationic lipids, contrary to conventional formulations. The invention liposome is also unique in that it utilizes low gel to fluid phase transition temperature lipids in its membrane.

Claims

1. A liposome composition for delivery of a therapeutic agent, comprising:

(a) From 1 to 10 mol percent of one or more lipids derivatized with a hydrophilic polymer

(b) the remainder of the lipids not containing cholesterol, sterols or derivatives thereof and not bearing a positive net charge when between pH 5 and 9, wherein said lipids possess a measurable gel to fluid lipid membrane phase transition temperature that exists between 10 and 45 degrees Celsius when each unique lipid component is measured individually in the fully-hydrated state between pH 5 and 9.

(c) a therapeutic or diagnostic agent, having a molecular weight greater than 3000 Daltons, that is completely encapsulated inside the liposome.

2. The composition of claim 1, wherein the therapeutic agent comprises a peptide, nucleotide or polysaccharide of a naturally occurring or chemically modified molecular structure.

3. The liposome of claims 1 and 2, wherein one or more lipids are selected from the group consisting of:

phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, phosphatidylethanolamine, or sphingomyelin.

4. The liposome of claims 1-3 consisting of a size between 30 and 1500 nm.

5. The liposome of any one of claims 1-4, wherein the acyl chains are selected from the group consisting of:

myristoyl (14 carbons per chain), or palmitoyl (16 carbons per chain).

6. The liposome of claim 1-5 wherein said lipid derivatized polymer is a phosphatidylethanolamine derivatized with polyethylene glycol.

7. The liposome of claim 1-6 wherein said lipid derivatized polymer is a lipid conjugated hydrophilic polymer that extends circulation time in blood at least two fold over a comparable liposome of composition and size which lacks said lipid derivatized polymer.

8. A liposome composition for delivery of a therapeutic agent, comprising:

(a) From 1 to 10 mole percent of one or more lipids derivatized with a hydrophilic polymer

(b) the remainder of the lipids not containing cholesterol, sterols or derivatives thereof, and not bearing a positive net charge when between pH 5 and 9, wherein said lipids as a mixture have a measurable gel to fluid lipid membrane phase transition temperature between 10 and 45 degrees Celsius when the lipid mixture is measured in the fully-hydrated state between pH 5 and 9.

(c) a therapeutic or diagnostic agent, having a molecular weight greater than 3000 Daltons, that is completely encapsulated inside the liposome.

9. The composition of claim 8, wherein the therapeutic agent is a peptide, nucleotide or polysaccharide of a naturally occurring or chemically modified molecular structure.

10. The liposome of claims 8 and 9, wherein one or more lipids are selected from the group consisting of:

phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, phosphatidylethanolamine, or sphingomyelin.

11. The liposome of claims 8-10 consisting of a size between 30 and 1500 nm.

12. The liposome of any one of claims 8-11, wherein the acyl chains are selected from the group consisting of:

myristoyl (14 carbons per chain), palmitoyl (16 carbons per chain).

13. The liposome of claim 8-12 wherein said lipid derivatized polymer is a phosphatidylethanolamine derivatized with polyethylene glycol.

14. The liposome of claim 8-13 wherein said lipid derivatized polymer is a lipid conjugated hydrophilic polymer that extends circulation time in blood at least two fold over a comparable liposome of composition and size which lacks said lipid derivatized polymer.